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Abstract 
Hutchinson-Gilford Progeria Syndrome (progeria) is an extremely rare childhood isorder characterized by precocious enility which 
presents features imilar to those seen in human aging. We have previously described a consistent increase of the glycoprotein gp200 in 
progeria skin fibroblasts in vitro. Here we extend these glycosylation studies and present evidence for the existence of two types of 
progeria skin fibroblasts. These two forms, called D- and D +, are distinguished by their response to the lectin DSA. In the D- group, 
DSA bound glycoproteins from progeria fibroblast strains AG03513B and AG10750 with markedly lower affinities compared with 
glycoproteins from three control fibroblast strains. In the D ÷ group, DSA binding to glycoproteins from four other progeria strains 
AG01972A, AG06297A, AG06917 and AG03198, was comparable to controls. Discrimination by DSA is the most distinctive feature of 
the D- and D ÷ groups, in contrast to binding of lectins Con A, GNA, PHA-L, RCA120, AAA and PNA which show no such selectivity. 
The data are consistent with a model of altered glycosylation i  the D- type of progeria fibroblasts. 
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1. Introduction 
Hutchinson-Gilford Progeria Syndrome (progeria) is a 
childhood disorder which manifests elected features of 
premature aging. Since progeria has characteristics which 
bear a striking resemblance to those seen in the elderly, it 
is generally accepted as being one of the best models for 
human aging (reviewed by [1]). Individuals with progeria 
show skin changes (e.g., thick and inelastic, resembling 
scleroderma, in the hip region, or thin and taut on the 
face), decreased subcutaneous tissue (fat and muscle) and 
alopecia. Skeletal effects include prominent joints, pyri- 
form thorax, dystrophic lavicles and acro-osteolysis, asso- 
Abbreviations: AAA, Aleuria aurantia agglutinin; Con A, Canavalia 
ensiformis (jack bean) agglutinin; DSA, Datura stramonium agglutinin; 
GNA, Galanthus nivalus agglutinin; HA, hyaluronic acid; PDGF, 
platelet-derived growth factor; PDL, population doubling level; PHA-L, 
Phaseolus vulgaris agglutinin; PMSF, phenylmethylsulfonyl fluoride; 
PNA, Arachis hypogaea (peanut) agglutinin; RCA120, Ricinus commu- 
nis agglutinin (M r 120 kDa); SDS, sodium dodecyl sulfate; WGA, wheat 
germ agglutinin. 
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ciated with osteoporosis. Complications of the cardio- 
vascular system and atherosclerosis typically result in death 
in the second decade of life [2-6]. 
Other degenerative changes which are often observed in 
the elderly, for example, cataracts, diabetes, neuronal 
changes and an increase in neoplasms, occur infrequently 
in progeria [1,6]. Thus, the study of progeria may be 
valuable in understanding the mechanisms by which alter- 
ations in particular tissues occur in human aging and 
which are presented in an exaggerated form in the progeria 
phenotype. The incidence of progeria has been estimated at 
1 in 8 million births [3] and only a small proportion of 
those affected have contributed skin fibroblasts by tissue 
biopsy [31]. Accordingly tissue samples are exceedingly 
rare and research depends primarily upon information de- 
rived from cultured cells. 
Presently the most useful clinical marker for the disor- 
der is increased urinary excretion of hyaluronic acid (HA) 
which is a component of connective tissue [5,7,8]. Elevated 
levels of HA have also been reported for progeria fibrob- 
lasts in vitro [5]. The value of HA as a marker in progeria 
and aging is unclear [9]: HA levels have been reported to 
be normal in some cases of progeria [10,11] and increased 
urinary excretion of HA has been observed in patients with 
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another premature aging disorder, Werner's syndrome 
[12,13]. Observations have been extended to studies in 
vitro where elevated production of HA by fibroblasts is 
also found for disorders exhibiting connective tissue de- 
fects including Werner's syndrome [14-16], Marfan syn- 
drome [17,18], osteogenesis mperfecta [19] and Coffin- 
Lowry syndrome [20]. On this basis, progeria may be 
considered a disorder which has a profound effect on the 
integrity of connective tissue. 
Glycoconjugates contribute functional diversity, partici- 
pate in development and differentiation, and are intimately 
involved in the structure and regulation of connective 
tissue [21,22]. Genetic defects in glycosylation are rare 
(reviewed by [22]), however there are some disorders uch 
as the mucopolysaccharidoses [23], HEMPAS disease [24], 
and a variant of Ehlers-Danlos syndrome with progeria-like 
features [25,26], in which defects in catabolism or process- 
ing enzymes in the glycosylation pathway have been re- 
ported. The consequences of aberrant glycosylation are 
highly variable but in each of the above cases, the defect 
has pleiotropic and deleterious effects on cellular function 
leading to multisystem involvement and widespread organ 
dysfunction. 
Little is known of the underlying biochemistry of 
progeria. We have reported elevated levels of the glyco- 
protein gp200 in progeria skin fibroblasts and suggested 
that glycosylation may be perturbed [27]. We now investi- 
gate this hypothesis by examining the interactions of a 
range of high apparent molecular weight glycoproteins 
(M r > 100 kDa) from progeria nd control fibroblasts with 
a panel of lectins having specificities covering a range of 
carbohydrate linkages. The results provide evidence for the 
existence in vitro of two types of progeria, distinguished 
by differential binding of glycoproteins to the lectin DSA. 
2. Materials and methods 
2.1. Cell culture, protein isolation, electrophoresis and 
electroblotting 
Fibroblast strains used in this work are described in 
Table 1. All strains were obtained from the Coriell Cell 
Repositories, New Jersey, USA. Culture of fibroblasts was 
done as previously described [27]. Soluble and membrane- 
bound cellular proteins were isolated according to the 
method of Springer [28] with minor modifications. Follow- 
ing trypsinization of fibroblast monolayers, cells were 
washed twice by resuspension i  phosphate-buffered saline 
(5 ml/106 cells) followed by centrifugation at 2000 rpm 
for 5 min. The final cell pellet was weighed and resus- 
pended in one volume of resuspension buffer (10 mM 
sodium phosphate, 0.14 M sodium chloride, 0.5% (w/v)  
Triton X-100, 0.5% (w/v)  sodium deoxycholate (pH 8.0)). 
The new volume was measured and an equal amount of 
freshly prepared lysis buffer (2% w/v  Triton X-100, 1 
Table 1 
Fibroblast rains: donor age and sex, and PDL ranges with percentage of 
maximum PDL. Progeria strains are denoted by an AG prefix and control 
strains by a GM prefix, according to[31] and [53], respectively 
Repository Donor age and sex PDL range % Maximum 
number PDL 
AG03513B 13 y, male 32-36 73-82 
AG10750 9 y, 4 mo, male 8 80 
AG03198 10 y, 8 mo, female 19-25 54-71 
AG01972A 13 y, 10 mo, female 30 88 
AG06297A 8 y, 2 mo, male 42 100 
AG06917 3 y, male 38 95 
GM02037A 13 y, male 45-63 64-90 
GM03348B 10 y, male 33-45 53-73 
GM05756 2 mo, male 44-48 61-67 
All biopsies were taken ante-mortem. Control samples were obtained 
from clinically unaffected (apparently normal) donors. PDL was calcu- 
lated at each harvest to give an estimate of cellular in vitro age [27]. 
Cellular lifespan i  vitro ('maximum PDL') of each strain was estimated 
by culturing cells continuously until senescence. PDL ranges were com- 
pared with the maximum PDL in each case to calculate a percent 
maximum PDL value. 
mM phenylmethylsulfonyl fluoride (PMSF), 5 mM iodo- 
acetamide, 10 mg/ml  soybean trypsin inhibitor (Boeh- 
ringer Mannheim) in resuspension buffer) was added and 
the cell suspension was stirred for 60 min at 4°C. Nuclei 
were pelleted for 10 min at maximum speed in a micro- 
centrifuge at 4°C. The supernatant was transferred to a 
fresh tube and 0.2 vols. 5% (w/v)  sodium deoxycholate 
was added, the solution was mixed by swirling then incu- 
bated on ice for 10 min. The sample was then centrifuged 
in an SW65 rotor at 44 000 rpm for 1-2 h and the clarified 
supernatant s ored at -80°C in small aliquots. 
Polyacrylamide gels (5%, w/v )  and samples were pre- 
pared according to the method of Laemmli [29]. SDS- 
PAGE was performed using an SE280 Tall Mighty Small 
Vertical Slab Unit (Hoefer Scientific Instruments, CA, 
USA). Samples of isolated cell protein (derived from 
5 • 105 cells) were boiled for 5 min in sample buffer and 
then loaded into a 1.4 cm wide well. Electrophoresis was 
at 20 mA or until the Bromophenol blue tracking dye had 
migrated to the end of the gel. Proteins were transferred 
using a TE Series Transphor Electrophoresis Unit (Hoefer 
Scientific Instruments) to Immobilon~M-P (PVDF, Milli- 
pore, MA, USA) according to the manufacturer's direc- 
tions. 
Glycoproteins were labelled using the Glycan Detection 
Kit (Boehringer Mannheim). Hydroxyl groups in the sugar 
component of glycoproteins were oxidized to aldehyde 
groups by treatment with sodium metaperiodate. Digoxy- 
genin was then covalently attached to the aldehydes via a 
hydrazide group. After electroblotting, lycoproteins were 
detected by enzyme immunoassay. Volumes of protein 
samples were adjusted so that they were normalized to cell 
number. The glycan detection kit was used according to 
the manufacturer's directions with modifications as de- 
scribed [27]. 
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2.2. Glycan differentiation 
Carbohydrate groups on glycoproteins were charac- 
terized using the glycan differentiation kit supplemented 
with additional ectins (Boehringer Mannheim; [30]) ac- 
cording to the manufacturer's instructions. After elec- 
trophoresis and electroblotting, lycoproteins were incu- 
bated with a lectin conjugated to the steroid hapten digoxy- 
genin. Lectin-bound glycoproteins were then detected by 
enzyme immunoassay using a specific anti-digoxygenin 
antibody. 
added to a final concentration of 20 mM sodium phos- 
phate, 0.5% (w/v)  octyl glucoside (Calbiochem), 50 mM 
EDTA, 1% (v/v)  fl-mercaptoethanol (pH 7.2), and the 
SDS was diluted to 0.15% (w/v), then samples were 
boiled a further 2 min and cooled to room temperature. 
PMSF was added to 1 mM, Glycopeptide N-glycosidase F 
(200 U/ml; Boehringer Mannheim) was added to a final 
concentration of 6 U/ml  and samples were incubated at 
37°C for 18 h. Control samples, incubated under the same 
conditions but in the absence of enzyme, demonstrated the 
absence of non-specific digestion. 
2.3. Enzymatic deglycosylation 
Endoglycosidase H 
Protein was denatured by boiling for 2 min in the 
presence of 0.05% (w/v)  SDS then cooled to room tem- 
perature. Digestion buffer was added to give 25 mM 
sodium phosphate, 0.4% (v/v)  /3-mercaptoethanol (pH 
5.7), and SDS was diluted to 0.01% (w/v). The sample 
was again boiled for 2 min then cooled to room tempera- 
ture. PMSF was added to a final concentration of 1 mM. 
Endoglycosidase H (1 U/ml;  Boehringer Mannheim) was 
added to a final concentration of ~ 20 mU/ml  and the 
sample was incubated at 37°C for 20-24 h. Control sam- 
pies, incubated under the same conditions but in the ab- 
sence of enzyme, demonstrated the absence of non-specific 
digestion. 
Glycopeptide N-glycosidase F 
Samples were boiled as for endoglycosidase H but in 
the presence of 0.75% (w/v)  SDS. Digestion buffer was 
Neuraminidase (sialidase) 
Protein samples from progeria and control fibroblasts 
were diluted 1:1 with neuraminidase buffer (100 mM 
sodium acetate, 8 mM calcium chloride (pH 5.5)). Neu- 
raminidase (1 U/ml;  Boehringer Mannheim) was added to 
a final concentration f 38 mU/ml  and the samples incu- 
bated at 37°C for 60 min. Control samples, incubated 
under the same conditions but in the absence of enzyme, 
demonstrated the absence of non-specific digestion. 
3. Results 
Progeria fibroblast strains consistently fell into two 
distinct groups depending on their glycoprotein profiles. 
Lectin DSA demonstrated considerably less binding to 
glycoproteins from the progeria strain AG03513B than to 
glycoproteins from the control strains GM02037A, 
GM03348B and GM05756 (Fig. 1, Panel A). To confirm 
that comparable l vels of total glycoprotein were present 
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Fig. 1. Panel A: DSA profiles of progeria fibroblast rain AG03513B (PDL 35), and control fibroblast rains GM02037A (PDL 62), GM03348B (PDL 
35) and GM05756 (PDL 48). Panel B: DSA profiles of progeria fibroblast rains AG01972A (PDL 30) and AG10750 (PDL 8). Panel C: DSA profiles of 
progeria fibroblast rains AG06297A (PDL 42) and AG06917 (PDL 38). 
M~A. Clark, A.S. Weiss / Biochimica et Biophysica Acta 1270 (1995) 142-148 145 
in these analyses, samples were examined in parallel by 
glycan detection as described in Section 2. These analyses 
showed equivalent signals for each cell strain (data not 
shown) confirming that the effect was not due to variations 
in total glycoprotein content. In contrast to low DSA 
binding for the progeria strain AG03513B, profiles of the 
three control strains were reproducibly similar. In addi- 
tional experiments involving AG03513B and GM02037A, 
lower binding by DSA to progeria glycoproteins was 
repeatedly observed. 
Observations with DSA were extended to the unrelated 
progeria strain AG10750 (Fig. 1, Panel B). Again there 
was markedly reduced binding of DSA to the progeria 
sample. As before, this dramatically reduced binding was 
due to changed affinity for the lectin and not to substantial 
gel-loading differences, because the total glycoprotein con- 
tent of the sample [27] was verified to be comparable to 
that of the control GM02037A (not shown). Accordingly 
the progeria strains AG03513B and AG10750 are classi- 
fied as members of the D- group because their glyco- 
proteins reproducibly displayed low DSA affinities. 
Four other progeria fibroblast strains were found to be 
members of a second group, based upon their apparently 
normal DSA affinities. Glycoproteins from progeria strain 
AG01972A showed reproducible affinity for DSA which 
was comparable to that of the control strain GM02037A 
(Fig. 1, Panels A and B). Similar levels of binding were 
also observed for glycoproteins from progeria strains 
AG06297A, AG06917 (Fig. 1, Panel C) and AG03198 (not 
shown). On the basis of their interactions with DSA these 
progeria strains are classified as members of the D ÷ 
group. To verify the binding of DSA, glycoproteins from 
GM03348B were digested with glycopeptide N-glyco- 
sidase F (results not shown) which resulted in a complete 
lack of detectable binding of DSA. 
In order to verify that the reduced binding of DSA in 
the D- group was a feature of this lectin and not an 
artifact of the detection system, additional ectins were 
used to examine AG03513B alongside GM02037A. DSA 
profiles were compared in parallel with Con A profiles for 
these two cell strains. Con A was chosen because the 
profiles of the two strains for this lectin were reproducibly 
similar in pattern and intensity. Exceptions were increased 
binding to a band at ~ 200 kDa in AG03513B, consistent 
with elevated gp200 [27], and decreased binding to a broad 
band at ~ 116 kDa; the rest of the profiles were essen- 
tially identical (Fig. 2). By comparing DSA and Con A 
profiles, it was possible to account for variations in differ- 
ent sample preparations or loading differences between 
analyses. Different preparations of protein were used to 
avoid possibly recurring systematic bias. Verification of 
the affinity of Con A for the carbohydrate components of 
glycoproteins was established by digestion with endogly- 
cosidase H which removed all detectable Con A recogni- 
tion sequences in extracts of these cells (not shown). 
Furthermore, cells for these protein preparations were cho- 
kDa 
G|yc~n Con A 
I I 
~,Go~s~ G~o~OS ~ ~,oos~ o~o~o~ ~ 
f 
180-- 
116~ 
!i~ ~  
, 3 ¸ 
Fig. 2. Glycoprotein ('glycan') and Con A profiles of progeria fibroblast 
strain AG03513B (PDL 35) and control fibroblast train GM02037A 
(PDL 47). 
sen such that they were from different batches of frozen 
stock and at different population doubling levels. Multiple 
comparisons done in this way confirmed that the D- 
results were DSA-specific. Additional lectins extended 
these observations and confirmed the distinctive nature of 
DSA analyses (see below). 
D- and D ÷ groups could not be distinguished using 
lectins Con A, GNA, PHA-L, RCA120, AAA or PNA. 
This extended the interpretation of Con A analyses that 
observations with DSA were independent of the nature of 
the detection system. 
Consistent with a model of decreased domains recognis- 
able by DSA, the sialic acid-binding lectin MAA also 
showed lower binding to strain AG03513B when com- 
pared with GM02037A (data not shown). To eliminate a 
model of a possible interference by terminal sialic acid 
kDa 
AG03513B GM02037A 
I + II + I 
180- -  
116- -  
Fig. 3. DSA profiles of progeria fibroblast rain AG03513B (PDL 35) 
and control fibroblast rain GM02037A (PDL 56) in the absence of( - ) 
and following ( + ) neuraminidase digestion. 
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Fig. 4. PNA profiles of progeria fibroblast rain AG03513B (PDL 34) 
and control fibroblast rain GM02037A (PDL 55) in the absence of( - ) 
and following (+) neuraminidase digestion. 
which is known to interfere with binding of DSA [32], 
glycoproteins from AG03513B and GM02037A were 
treated with neuraminidase (sialidase) to remove sialic acid 
then incubated with DSA (Fig. 3). Digestion may have 
resulted in a slight increase in binding of DSA to 
AG03513B but low binding was still observed in contrast 
to GM02037A. The banding pattern of GM02037A (and 
possibly of AG03513B) changed after digestion with neu- 
raminidase thereby confirming the action of the enzyme, 
yet labelling of control glycoproteins was still intense. Fig. 
3 shows typical D- characteristics for AG03513B which 
were not substantially enhanced by neuraminidase treat- 
ment. This indicates that an effect other than altered 
sialylation in AG03513B is responsible for the D- phe- 
nomenon. Total glycoprotein content of the same extracts 
of AG03513B and GM02037A ([27]; not shown) indicated 
there was comparable signal from both strains confirming 
that comparable amounts of total glycoprotein were pre- 
sent. Evidence that neuraminidase did not damage the 
progeria material was obtained from separate analyses with 
the lectins PNA (Fig. 4) and RCA120 (not shown). These 
lectins recognise unsubstituted galactose residues and ter- 
minal unsubstituted galactose, respectively [33]. Neu- 
raminidase digestion of AG03513B and GM02037A per- 
mitted binding of the lectin compared with the undigested 
samples. These data confirm that the D-  observations 
were not due to obstruction of DSA binding by sialic acid. 
4.  D iscuss ion  
High M r (> 100 kDa) glycoproteins from progeria 
fibroblast strains AG03513B and AG10750 reproducibly 
demonstrate lower affinities for lectin DSA. Four other 
progeria fibroblast strains do not show this effect. This 
leads us to propose the existence of two types of progeria 
strains distinguished by low (D-)  or apparently normal 
(D ÷) binding of glycoproteins to the lectin. Differential 
binding of DSA contrasts with the relatively indistinguish- 
able binding in each case of Con A, GNA, PHA-L, 
RCA120, AAA and PNA. Lectin Con A detects sugar 
groups which are primarily of the high-mannose, hybrid 
and biantennary types. GNA binds sugars with terminal 
mannose residues. The results with these lectins suggest 
that there are no apparent differences between any of the 
progeria fibroblast strains and the control strains examined 
with regard to the formation of oligosaccharides of high- 
mannose types. PHA-L has preferred recognition se- 
quences which contain highly branched N-glycans with 
outer galactose residues and an a-mannose residue which 
is substituted with /3(1-6) N-acetyllactosamine antennae. 
The lack of major differences between glycoproteins from 
progeria and control fibroblasts also suggests that the 
progeria cells are not deficient in the biosynthesis of 
/3(1-6) glycans. Similarly with lectin RCA-120, there 
were no major apparent differences between progeria and 
control samples. This lectin recognises and binds terminal 
galactose residues and galactose which is l inked/3(1-3) to 
N-acetylglucosamine. This latter linkage type is also 
recognised by PNA. AAA lectin recognises fucose residues 
indicating that there were no obvious nor consistent differ- 
ences between progeria samples and control samples with 
regards their degree of fucosylation. These data together 
indicate that there is no obvious defect in the progeria 
fibroblasts examined to synthesise a wide range of glycans 
apart from those detected by DSA. 
The results are fully consistent with a model of signifi- 
cant differences in progeria strains AG03513B and 
AG10750 compared with other progeria and control fi- 
broblast strains examined at the level of glycoprotein 
oligosaccharides with recognition sequences for DSA (see 
below). Compared to D ÷ and control strains, data suggest 
a reduction of intensity for D- strains of 2- to 4-fold. This 
is an estimate only because the lectin differentiation sys- 
tem does not necessarily generate colour as a linear func- 
tion of glycoprotein concentration [30,34]. The differences 
which are manifested by these two progeria strains may 
not represent the primary defect in progeria but may reflect 
secondary changes. Nevertheless the differences are dra- 
matic and therefore significant to the underlying biochem- 
istry of the progeria phenotype. 
DSA has complex and specific requirements for the 
recognition of carbohydrate groups. A strong recognition 
sequence for DSA is /3(1-4) oligomers of GlcNAc [32,37] 
and a clustering of these groups may be necessary for DSA 
to bind strongly [38]. Of relevance to mammalian glyco- 
sylation mechanisms, the most potent binding of DSA 
occurs with carbohydrates which are of the tetraantennary 
N-acetyllactosamine-type {Gal/3(1-4)GlcNAc} [32]. The 
DSA binding results indicate that D- progeria strains may 
contain significantly less of these recognition sites than in 
the D ÷ progeria nd control strains. 
Factors which can negatively influence the binding of 
DSA, and therefore may be causal in the reduction of 
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binding of this lectin to glycoproteins from AG03513B 
and AG10750, are the presence of terminal sialic acid 
residues and fucose residues in the core sequence of the 
oligosaccharide [32,37]. While it is not possible to exclude 
effects such as sulfation of hexosamines, DSA is not 
reported to be inhibited by such phenomena, and other 
lectins described here display no significant diminution of 
binding when D + and D-  forms are compared. Neu- 
raminidase digestion demonstrated that the relatively low 
binding of DSA to AG03513B was not due to interference 
by terminal sialic acid residues ince their removal did not 
substantially increase binding of DSA (Fig. 3). This is in 
marked contrast o the substantially increased binding ob- 
served after neuraminidase treatment involving lectin 
RCA120, and PNA (Fig. 4). 
Several alternative biochemical models can be proposed 
to account for the D-  phenotype. One possibility arises 
from altered levels of accessible precursor metabolites 
involved in a functional glycosylation environment such as 
that proposed for Wiskott-Aldrich syndrome [39]. An 
attractive hypothesis postulates the involvement of an en- 
zyme which participates in the synthesis or modification of 
DSA recognition sequences. This is currently under inves- 
tigation (O'Brien, M.E. and Weiss, A.S., unpublished). 
Consistency and similarities among the control fibrob- 
last strains in terms of their general ectin profiles, and, 
indeed, the similarities of the profiles of the D + strains 
with the controls, and similarities within the D- group 
argue against differences in the type and extent of glyco- 
sylation between individuals, and between tissues [35] as 
the source of the D- and D + phenomena. Glycosylation 
has been shown to vary as a function of age (e.g., [36]) 
thus we cannot exclude the possibility that D- results 
might be a consequence of changes in the individual 
donors by the time of biopsy or during the culturing of 
progeria fibroblasts. However, specific culture effects are 
unlikely as three of the strains (AG06917, AG06297A and 
AG01972A) were already close to senescence at the time 
of receipt in the laboratory (Table 1) yet gave D ÷ results 
similar to AG03198 which was farthest from senescence. 
All four strains gave DSA profiles similar to the controls. 
Progeria and control fibroblasts were used at PDL 
values 40-85% of their maximum in vitro life-span and all 
cultures were in Phase II (as defined by [40]). All donors 
were classified as classical progeria and there seem to be 
no consistent features such as sex, age or race of the 
donors, biopsy site or culture time in the laboratory which 
may correlate with differences between the D- and D ÷ 
groups [31]. 
Division of progeria into D- and D ÷ groups is consis- 
tent with the varied and often contradictory results pre- 
sented in the literature for various progeria samples. Het- 
erogeneity has been reported in many different assays 
including response to epidermal growth factor [41], levels 
of platelet-derived growth factor (PDGF; [42]), insulin 
resistance [43], DNA repair capacity [44,45], thermolabile 
enzymes [46], expression of cellular oncogenes [42,47], 
and fibroblast morphology [27,41]. With particular egard 
to AG03513B, Winkles et al. [42] found that this strain 
constitutively expressed PDGF mRNA but this was not 
observed in two other progeria strains (AG06917 and 
AG06297). This is fully consistent with our grouping of 
these strains as D- and D ÷ types, respectively. Winkles et 
al. raised the possibility that the property they observed 
may be related to membership of a sub-type of progeria, 
which is thought o be a genetically heterogeneous di ease 
[42]. Brown et al. [48] proposed the existence of comple- 
mentation groups in progeria, based upon their observa- 
tions of the effects of co-cultivation of progeria with 
normal fibroblasts on DNA repair in progeria cells. 
The carbohydrate component of a glycoprotein can play 
a significant role in the physiological behaviour of the 
molecule, and the biological context and state of the cell or 
organism may dictate the set of glycoforms which are 
produced [22,35]. Glycoproteins function in a physico- 
chemical role, e.g., in determining the conformation of the 
protein core and protecting it from proteolysis, and in a 
biological role such as mediators of cell adhesion, cell-cell 
recognition, contact inhibition, maintenance of cell mor- 
phology, regulation of catabolism, and transport of newly 
synthesized glycoproteins to the extracellular environment 
[49-51]. With variations in linkage positions, branching, 
and the ability to carry substituent groups, carbohydrate 
groups have the potential for enormous biological speci- 
ficity (reviewed by [22,52]). Altered glycosylation i  the 
D- form of progeria may have dramatic and possibly 
deleterious effects on cellular function and consequently 
influence tissue behaviour and appearance. 
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